Peer-reviewed veterinary case report
Protein in urine in dogs treated with toceranib phosphate
By Piscoya, Sindy L et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2018·Cornell University College of Veterinary Medicine - Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A retrospective study of proteinuria in dogs receiving toceranib phosphate.
- Species:
- dog
Plain-English summary
A group of dogs being treated with toceranib phosphate, a medication often used for cancer, were monitored for protein in their urine, a condition known as proteinuria. Out of 49 dogs that initially showed no signs of proteinuria, 12 developed this issue during treatment. The protein levels varied, and the duration of treatment ranged from about two months to over two years. The study suggests that while some dogs may develop proteinuria while on this medication, it’s important for pet owners to have their dogs regularly checked with urine tests to catch any changes early.
People also search for: dog protein in urine treatment · toceranib phosphate side effects · dog cancer medication proteinuria
Abstract
The incidence of proteinuria in humans receiving tyrosine kinase inhibitors has been well-documented. Reports of proteinuria with this class of drugs are limited in veterinary medicine. This retrospective study describes the incidence, severity, and progression of proteinuria in 55 dogs treated with toceranib phosphate, with or without concurrent glucocorticoid or NSAID (non-steroidal anti-inflammatory drug). Six dogs were proteinuric at baseline. Twelve of the 49 dogs that were not proteinuric at baseline developed proteinuria while receiving toceranib phosphate. Median urine protein:creatinine (UPC) ratio when proteinuria developed was 0.75 (range: 0.6 to 4.9). There was no association with intermittent glucocorticoid or NSAID use and development of proteinuria (= 0.5 and= 0.7, respectively). Overall duration of toceranib phosphate treatment ranged from 70 to 802 days in proteinuric dogs and 28 to 1285 days in non-proteinuric dogs. Our results indicate a subset of dogs receiving toceranib phosphate may develop proteinuria; careful monitoring with serial UPCs is recommended.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29910474/